Abbott Laboratories (ABT) Stock: Price, Forecast & Analyst Target
Abbott Laboratories (ABT) — MoonshotScore 70/100 (Strong band), calculated Oct 7, 2026. Price $98.17 (-1.93%), as of the Oct 6, 2026 trading session; market cap $170B. Expected results Oct 14, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 30.34× (market value Oct 6, 2026; cash Jun 30, 2026) · expected results Oct 14, 2026
Abbott Laboratories · ABT · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-12: Abbott Laboratories sells medical devices, diagnostic systems and tests, nutritional formulas, and established medicines; its results therefore reflect several distinct healthcare demand engines rather than a pure device cycle. The case now hinges on whether rising sales can again produce rising operating earnings while expenses absorb more gross profit and the cash balance moves lower.
Price as of Oct 6, 2026
Key Statistics
MoonshotScore v2 · Abbott Laboratories (ABT)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, but a strained balance sheet. Business Quality: Elite; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Rising.
- quarterly revenue $12.59B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 2 of 8
- expected results Oct 14, 2026
Helping: business quality, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 70 | Strong | |
| 70 | Strong | |
| 70 | Strong | |
| 70 | Strong | |
| 70 | Strong | |
| 70 | Strong |
The score was 70 in the stored Oct 6, 2026 snapshot and remains 70 in the current publication computed Oct 7, 2026 (0); the largest pillar moves were Growth Durability -1 and Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $98.17 | |
| Change on the day | -1.93% | |
| 52-week range | $81.97–$135.13 | |
| Market capitalisation | $170B | |
| Price / earnings (trailing) | 31.57 | |
| Shares traded on the day | 9.05M | |
| Beta (volatility vs the S&P 500) | 0.59 | |
| Dividends per share (last 12 months) | $2.48 | |
| Dividend yield (last 12 months) | 2.53% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · in line with the recorded estimate
- · Earnings results · in line with the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
For the third quarter, we forecast adjusted earnings per share of $1.38 to $1.46 With that, we will now open the call for questions.
Philip Boudreau · Statement from
Chronological order, not a duration scale. Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Abbott Laboratories (ABT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 30, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 7, 2026, except a card that shows its own read date.
Watch the ABT film — every key number, told as a short cinematic story
~2 min · open the film
What is Abbott Laboratories (ABT), and what does it report?
Short answer · as of
Abbott earns revenue when hospitals and laboratories buy testing platforms, cartridges and automation; when clinicians use cardiovascular, diabetes and neuromodulation products; and when consumers or healthcare channels buy nutritional formulas and established generic medicines.
Research dated 2026-09-12.
Abbott earns revenue when hospitals and laboratories buy testing platforms, cartridges and automation; when clinicians use cardiovascular, diabetes and neuromodulation products; and when consumers or healthcare channels buy nutritional formulas and established generic medicines. Medical Devices is the largest reporting segment, but Diagnostics, Nutrition, and Established Pharmaceutical Products make consolidated revenue a measure of several different purchasing patterns.
That mix corrects the obvious reading of Abbott as simply a device maker. A movement in total sales may reflect procedure-related devices, recurring diagnostic consumption, nutrition demand, medicine volumes, or several of these at once, so the segment composition matters as much as the headline.
What do the latest results show for Abbott Laboratories (ABT)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $12.59B.
Research dated 2026-09-12.
The latest quarter delivered the strongest revenue and gross profit in the reported sequence, yet operating profit fell from the preceding period and net income and diluted earnings weakened. Selling, general and administrative expense rose sharply while research and development spending also increased, absorbing more than the added gross profit; this was a reversal in operating leverage, not a contraction in revenue.
Recent reported results cleared prevailing revenue and earnings estimates, while management framed the near-term outlook through an adjusted earnings range. That distinction matters because the income statement shows weaker reported profit conversion even as the expectation record and management outlook emphasize adjusted earnings.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $12.59B Jun 30, 2026
- Latest quarter · R&D
- $882.00M Jun 30, 2026
- Latest quarter · SG&A
- $3.98B Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $1.78B Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $12.59B | $882.00M | $3.98B | $1.78B |
| Mar 31, 2026 | $11.16B | $756.00M | $3.26B | $1.84B |
| Dec 31, 2025 | $11.46B | $735.00M | $3.13B | $2.25B |
| Sep 30, 2025 | $11.37B | $785.00M | $3.10B | $2.06B |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $12.59B Jul 16, 2026
- Latest report · revenue estimate
- $12.52B Jul 16, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 16, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 16, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 16, 2026 | $12.59B | $12.52B | $1.3100 | $1.2800 |
| Apr 16, 2026 | $11.16B | $11.00B | $1.1500 | $1.1400 |
| Jan 22, 2026 | $11.46B | $11.80B | $1.5000 | $1.5000 |
| Oct 15, 2025 | $11.37B | $11.39B | $1.3000 | $1.3000 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $12.59B | $928M | $0.53 (diluted) |
| Q1 FY2026 | $11.16B | $1.08B | $0.62 (diluted) |
| Q4 FY2025 | $11.46B | $1.78B | $1.02 (diluted) |
| Q3 FY2025 | $11.37B | $1.64B | $0.94 (diluted) |
What are the financial strengths and risks for Abbott Laboratories (ABT)?
Short answer
Cash and short-term investments were $5.60B at the Jun 30, 2026 balance-sheet date. Operating cash flow was $2.49B for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has remained positive throughout the reported quarterly sequence and strengthened in the latest period, giving Abbott internally generated funds despite weaker reported earnings. Liquidity ratios remain workable, and the available distress screen does not signal immediate balance-sheet strain.
Debt nevertheless stands far above cash and investments, leaving Abbott in a net-debt position. Cash and short-term investments have declined across the reported window, including consecutive drops from the recent peak, so sustained expense growth, weaker profit conversion, or a retreat in operating cash flow would reduce financial flexibility.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 8 reported quarters.
- Rich valuation — a P/E of 31.57 runs well above the Healthcare sector’s ~21.60x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $2.49B Jun 30, 2026
- Previous quarter · operating cash flow
- $1.31B Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $2.49B | Provider sign conflict |
| Mar 31, 2026 | $1.31B | −$399.00M |
| Dec 31, 2025 | $3.31B | −$689.00M |
| Sep 30, 2025 | $2.79B | −$496.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Abbott Laboratories (ABT)?
Short answer · as of
The next earnings report is expected on Oct 14, 2026.
Research dated 2026-09-12.
The next earnings release should be read through revenue quality and conversion: whether sales remain near the recent high, whether operating profit resumes growing with gross profit, and whether selling and administrative costs retreat from their latest step-up. Reported adjusted earnings can then be compared with management’s stated range and the prevailing estimate, while revenue can be tested against the market’s expected expansion.
Cash is the other live check. A rebound in cash and short-term investments alongside continued operating cash generation would ease the tension between healthy cash inflow and the declining balance; another drop would keep attention on uses of cash and the gap between debt and liquidity.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
For the third quarter, we forecast adjusted earnings per share of $1.38 to $1.46 With that, we will now open the call for questions.
Philip Boudreau ·
How does Abbott Laboratories compare with its peers?
Short answer
Abbott Laboratories's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
A focused medical-device company rises and falls mainly with adoption of its devices and the clinical activity that supports their use. Abbott also sells laboratory systems and consumable tests, pediatric and adult nutrition, and established medicines, so consolidated performance combines institutional, clinical, and consumer demand.
Medical Devices remains the largest segment, but Diagnostics and Nutrition are substantial businesses in their own right. This breadth can keep weakness in a particular healthcare category from defining the entire company, while also making group revenue a less precise indicator of device execution than it would be for a specialist.
| Company | Price | Market value | Score |
|---|---|---|---|
| $83.39 Oct 6, 2026 | $31.5B | 95 5-pillar Oct 7, 2026 | |
| $317.13 Oct 6, 2026 | $12.5B | 95 5-pillar Oct 7, 2026 | |
| $37.53 Oct 6, 2026 | $167B | 91 5-pillar Oct 7, 2026 | |
| $86.69 Oct 6, 2026 | $49.9B | 90 5-pillar Oct 7, 2026 | |
| $211.07 Oct 5, 2026 | $20.6B | 87 5-pillar Oct 7, 2026 | |
| $26.84 Oct 6, 2026 | $11.3B | 87 5-pillar Oct 7, 2026 | |
| $140.75 Oct 6, 2026 | $268B | 84 5-pillar Oct 7, 2026 | |
| $42.19 Oct 6, 2026 | $62.7B | 83 5-pillar Oct 7, 2026 | |
| $86.78 Oct 6, 2026 | $111B | 80 5-pillar Oct 7, 2026 | |
| $89.68 Oct 6, 2026 | $17.4B | 80 5-pillar Oct 7, 2026 | |
| $278.50 Oct 6, 2026 | $107B | 79 5-pillar Oct 7, 2026 | |
| $374.51 Oct 6, 2026 | $340B | 74 5-pillar Oct 7, 2026 | |
| Abbott Laboratories (ABT) — this page | $98.17 | $170B | 70 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $92.00 – $134.00
- Consensus target
- $119.91
- Median target
- $120.00
Consensus record · Captured .
Measured against a quoted price of $98.17 (as of Oct 6, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 30, 2026
- Transactions
- 44
- Identified insiders
- 18
- Purchases
- 3
- Sales
- 4
- Other transactions
- 37
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 82.3% Period end Jun 30, 2026
- Previous quarter · ownership
- 78.8% Prior to period end Jun 30, 2026
- Reporting holders
- 3,068 Period end Jun 30, 2026
- Previous quarter · holders
- 3,203 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 152,563,476 |
| Vanguard Capital Management LLC | 113,750,994 |
| State Street Corp | 80,926,234 |
| Charles Schwab Investment Management INC | 59,674,507 |
| Sixth Street Partners Management Company, L.P. | 59,674,507 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Abbott Laboratories (ABT)?
What Investors Ask About Abbott Laboratories (ABT) — Healthcare
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why is Abbott not simply a medical-device company?
Abbott’s largest segment is Medical Devices, but the company also earns substantial revenue from Diagnostics, Nutrition, and Established Pharmaceutical Products. Its headline results therefore combine device adoption with laboratory testing, nutritional demand, and medicine sales.
Why did Abbott’s latest revenue gain not lift operating profit?
Gross profit increased, but selling, general and administrative expense rose sharply and research spending also moved higher. Those expenses more than absorbed the incremental gross profit, leaving operating profit below the preceding period.
What does Abbott’s Established Pharmaceutical Products segment add to the business mix?
The segment supplies generic medicines across a broad set of conditions, adding a pharmaceutical demand stream alongside devices, diagnostics, and nutrition. It makes Abbott’s consolidated sales less dependent on medical procedures alone.
How does Abbott’s falling cash balance fit with positive operating cash flow?
Positive operating cash generation and a declining cash balance can coexist when cash uses elsewhere exceed the period’s inflow. For Abbott, the important observation is that operating cash flow remains positive while cash and short-term investments have moved lower and debt remains materially larger than liquidity.
What is the ABT stock price today?
The last price recorded on this page for Abbott Laboratories (ABT) is $98.17, as of the Oct 6, 2026 trading session (source: Financial Modeling Prep (FMP) quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ABT price target?
The analyst consensus price target for Abbott Laboratories (ABT) is $119.91 (range $92.00 to $134.00, median $120.00), per FMP data captured Oct 7, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
When are ABT's next earnings?
The next earnings date listed on this page for Abbott Laboratories (ABT) is Oct 14, 2026. Companies sometimes move report dates, so the company's own announcement is the final word on timing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (83 figures)
The 83 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Philip Boudreau (Jul 16, 2026): For the third quarter, we forecast adjusted earnings per share of $1.38 to $1.46 With that, we will now open the call for questions. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Abbott Park, IL | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "100 Abbott Park Road, Abbott Park, IL, 60064-6400, US". The FMP company description names North Chicago, Illinois as the headquarters; this page uses the address in this row. |
FMP — 72 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $98.17 | FMP | Financial Modeling Prep (FMP) quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. | |
px.change | Change on the day | -1.93% | FMP | Financial Modeling Prep (FMP) quote | |
px.mcap | Market capitalization | $170B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-06. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$1.93 | FMP | Financial Modeling Prep (FMP) quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $12.59B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $81.97–$135.13 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 31.57 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 9.05M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.59 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Robert Ford | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 115,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $43.08B, net result $7.07B; FY2022 revenue $43.65B, net result $6.93B; FY2023 revenue $40.11B, net result $5.72B; FY2024 revenue $41.95B, net result $13.40B; FY2025 revenue $44.33B, net result $6.52B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Medical Devices $21.39B · Diagnostic Products $8.94B · Nutritional Products $8.45B · Established Pharmaceutical Products $5.54B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 56.8% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $12.59B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $882.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $3.98B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $1.78B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $11.16B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $756.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $3.26B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $1.84B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $11.46B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $735.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $3.13B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $2.25B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $11.37B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $785.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $3.10B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $2.06B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-16.revenue_actual | Revenue · reported — report date 2026-07-16 | $12.59B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-16.revenue_estimated | Revenue · estimate — report date 2026-07-16 | $12.52B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-16.eps_actual | EPS · reported — report date 2026-07-16 | $1.3100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-16.eps_estimated | EPS · estimate — report date 2026-07-16 | $1.2800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-16.revenue_actual | Revenue · reported — report date 2026-04-16 | $11.16B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-16.revenue_estimated | Revenue · estimate — report date 2026-04-16 | $11.00B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-16.eps_actual | EPS · reported — report date 2026-04-16 | $1.1500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-16.eps_estimated | EPS · estimate — report date 2026-04-16 | $1.1400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-22.revenue_actual | Revenue · reported — report date 2026-01-22 | $11.46B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-22.revenue_estimated | Revenue · estimate — report date 2026-01-22 | $11.80B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-22.eps_actual | EPS · reported — report date 2026-01-22 | $1.5000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-22.eps_estimated | EPS · estimate — report date 2026-01-22 | $1.5000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-15.revenue_actual | Revenue · reported — report date 2025-10-15 | $11.37B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-15.revenue_estimated | Revenue · estimate — report date 2025-10-15 | $11.39B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-15.eps_actual | EPS · reported — report date 2025-10-15 | $1.3000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-15.eps_estimated | EPS · estimate — report date 2025-10-15 | $1.3000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $5.60B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $2.49B | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $1.11B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $32.61B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 3.35× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $2.49B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $1.31B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$399.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $3.31B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$689.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $2.79B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$496.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $92.00 – $134.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 7, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $119.91 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 7, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $120.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 7, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 44 transactions · 3 purchases, 4 sales, 37 other transactions · 18 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 30, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 82.3% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 78.8% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 3,068 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 3,203 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 152,563,476 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Vanguard Capital Management LLC — shares in provider snapshot | 113,750,994 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | State Street Corp — shares in provider snapshot | 80,926,234 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Charles Schwab Investment Management INC — shares in provider snapshot | 59,674,507 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Sixth Street Partners Management Company, L.P. — shares in provider snapshot | 59,674,507 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 14, 2026 | UNRECORDED | Stored earnings-calendar observation — Captured 2026-08-31 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 30.34× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $5.60B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-06. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $2.48 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-07, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.53% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-16.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($12.59B) with the recorded estimate ($12.52B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-16.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($1.3100) with the recorded estimate ($1.2800) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 70 of 100 · Strong · pillars 84 / 36 / 58 / 72 / 61 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 70 (stored snapshot Oct 6, 2026) → 70 (current publication computed Oct 7, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-07-16. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-16.revenue_actual,earn.history.depth.2026-07-16.revenue_estimated,earn.history.depth.2026-07-16.revenue_actual.comparison,earn.history.depth.2026-07-16.eps_actual.comparison,earn.history.depth.2026-07-16.eps_actual,earn.history.depth.2026-07-16.eps_estimated,earn.history.depth.2026-04-16.revenue_actual,earn.history.depth.2026-04-16.revenue_estimated,earn.history.depth.2026-04-16.eps_actual,earn.history.depth.2026-04-16.eps_estimated,earn.history.depth.2026-01-22.revenue_actual,earn.history.depth.2026-01-22.revenue_estimated,earn.history.depth.2026-01-22.eps_actual,earn.history.depth.2026-01-22.eps_estimated,earn.history.depth.2025-10-15.revenue_actual,earn.history.depth.2025-10-15.revenue_estimated,earn.history.depth.2025-10-15.eps_actual,earn.history.depth.2025-10-15.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Devices The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Medical Devices: $21.39B; Diagnostic Products: $8.94B; Nutritional Products: $8.45B; Established Pharmaceutical Products: $5.54B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-16 | FMP | Financial Modeling Prep (FMP) earnings |
| Management outlook — dated call excerpts | Captured record · 1 entry
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-16 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Next earnings report | Date: 2026-10-21; EPS estimate: $1.43 per share; Revenue estimate: $12.99B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Trailing twelve-month ratio set | Quick ratio: 0.97; Current ratio: 1.38; Debt to equity: 0.64; Net margin: 11.6%; Gross margin: 56.8%; Operating margin: 17%; Return on assets: 5%; Return on equity: 10.5% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 3.23; Piotroski F-score: 5 Altman Z below 1.8 is the conventional distress zone. For a company holding large cash against negative retained earnings the score mostly reflects the retained-earnings term. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) financial scores |
| Cash, investments and debt | Total debt: $32.61B; Liquidity basis: cash and short-term investments; Total liabilities: $57.45B; Cash and short-term investments: $5.60B; Cash and investments: $6.71B; Long-term investments: $1.11B; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $6.71B; Cash and short-term investments: $5.60B; Long-term investments: $1.11B; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $5.60B; Decline: $2.19B; Opening balance: $7.79B; Average change per period: $312.10M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$27.00B; Total debt: $32.61B; Cash and investments: $5.60B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
Data provided for informational purposes only.
ETFs that hold ABT
Funds in our ETF coverage that list ABT among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| VHT ETF | 2.90% | |
| ProShares - Ultra Health Care (RXL) | 2.48% | |
| IXJ ETF | 2.44% |